Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
International Association for the Treatment of Sexual Offenders and treatment targets (such as cognitive distortions). Responsivity issues are the parts that affect how much the client(s) benefit or fail to benefit from the treatment and care programs. This proves that the treatment of sexual offenders has to be specific and different than another offenders treatment. Treatment of sexual offenders is very complicated and it is crucial to take the proper guidelines for the treatment to not only be successful but also to be long-lasting. Youths between the ages of 12-18 who have been either officially charged with a sexual crime or have performed an act that could be